Amg 337
Stomach Neoplasms
AmgenSmall moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 81/ 100
Competitive context
35 Active assets in the Stomach Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Seagen, a wholly owned subsidiary of Pfizer | Phase 4 | BBB |
Capecitabine SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 3 | BB |
Eloxatin SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Jazz Pharmaceuticals | Phase 3 | BB |
Pembrolizumab Merck Sharp & Dohme LLC | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Amg 337 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →